Skip to main content
Midas Edge

vTv Therapeutics Inc.

For the period ended Aug 6, 2026. Filed Aug 6, 2026.

View on SEC.gov

About this filing

A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.

Aug 6, 2026 · Filed Aug 6, 2026

VTVT$21.03-3.3%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits
Contents

EX-99.1 · (in thousands, except per share data)

(in thousands, except per share data)

Three Months EndedJune 30,Six Months EndedJune 30,
2026202520262025
(Unaudited) · (Unaudited)
Revenue$—$—$36,839$—
Operating expenses:
Research and development8,7704,10317,7486,933
General and administrative5,1603,6189,7587,291
Total operating expenses13,9307,72127,50614,224
Operating (loss) income(13,930)(7,721)9,333(14,224)
Interest income8122751,650606
Other income (expense), net64669721
Net (loss) income before income taxes and noncontrolling interest(13,054)(7,380)11,080(13,597)
Income tax provision————
Net (loss) income before noncontrolling interest(13,054)(7,380)11,080(13,597)
Less: net loss attributable to noncontrolling interest—(1,334)—(2,459)
Net (loss) income attributable to vTv Therapeutics Inc.$(13,054)$(6,046)$11,080$(11,138)
Net (loss) income attributable to vTv Therapeutics Inc. common shareholders$(13,054)$(6,046)$11,080$(11,138)
Basic net (loss) income per share of vTv Therapeutics Inc. Class A common stock$(1.05)$(0.92)$0.89$(1.69)
Basic weighted average number of vTv Therapeutics Inc. Class A common stock12,409,3166,587,07012,409,2976,584,969
Diluted net (loss) income per share of vTv Therapeutics Inc. Class A common stock$(1.05)$(0.92)$0.76$(1.69)
Diluted weighted average number of vTv Therapeutics Inc. Class A common stock12,409,3166,587,07014,541,7886,584,969
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.